-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 119.4%
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 119.4%
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Rating)'s share price rose 119.4% during mid-day trading on Monday . The stock traded as high as $13.75 and last traded at $11.85. Approximately 57,188,768 shares changed hands during trading, an increase of 415% from the average daily volume of 11,097,444 shares. The stock had previously closed at $5.40.
Virax Biolabs Group Stock Performance
About Virax Biolabs Group
(Get Rating)
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name.
Further Reading
- Get a free copy of the StockNews.com research report on Virax Biolabs Group (VRAX)
- Proposed Tesla Stock Split Drives EV Market Higher
- AutoNation Stock is Firing on All Pistons
- Is Nike An Undervalued Opportunity for Investors?
- Caterpillar Falls To Strong Support Near Bottom Of Range
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Rating)'s share price rose 119.4% during mid-day trading on Monday . The stock traded as high as $13.75 and last traded at $11.85. Approximately 57,188,768 shares changed hands during trading, an increase of 415% from the average daily volume of 11,097,444 shares. The stock had previously closed at $5.40.
Virax Biolabs Group Limited(纳斯达克代码:VRAX-GET Rating)周一午盘股价上涨119.4%,盘中一度涨至13.75美元,最新报11.85美元。全天约57,188,768股易手,较11,097,444股的日均成交量增加415%。该股此前收盘价为5.4美元。
Virax Biolabs Group Stock Performance
Virax Biolabs集团股票表现
About Virax Biolabs Group
关于Virax Biolabs集团
(Get Rating)
(获取评级)
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name.
Virax Biolabs Group Limited是一家生物技术公司,销售、分销和营销诊断试剂盒、医疗技术和个人防护产品,用于预防、检测、诊断和风险管理免疫学领域的病毒疾病。该公司提供ViraxClear品牌下的快速抗体IGC/IgM检测、抗原检测、聚合酶链式反应快速检测和中和抗体检测,以及医疗技术和个人防护产品,如ViraxCare品牌下的员工保护设备产品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Virax Biolabs Group (VRAX)
- Proposed Tesla Stock Split Drives EV Market Higher
- AutoNation Stock is Firing on All Pistons
- Is Nike An Undervalued Opportunity for Investors?
- Caterpillar Falls To Strong Support Near Bottom Of Range
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 免费获取StockNews.com关于Virax Biolabs Group(VRAX)的研究报告
- 拟议的特斯拉股票拆分推动电动汽车市场走高
- AutoNation股票正在向所有活塞开火
- 耐克对投资者来说是一个被低估的机会吗?
- 卡特彼勒跌至接近区间底部的强劲支撑
- AMD第二季度收益显著超出预期,AMD A买入吗?
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Virax Biolabs Group Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Virax Biolabs Group和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧